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Although Blastocystis is one of the most common enteric parasites, there is still much controversy surrounding the
pathogenicity and potential treatment options for this parasite. In this review we look at the evidence supporting
Blastocystis as an intestinal pathogen as shown by numerous case studies and several in vivo studies and the
evidence against. We describe the chronic nature of some infections and show the role of Blastocystis in
immunocompromised patients and the relationship between irritable bowel syndrome and Blastocystis infection.
There have been several studies that have suggested that pathogenicity may be subtype related. Metronidazole is
the most widely accepted treatment for Blastocystis but several cases of treatment failure and resistance have been
described. Other treatment options which have been suggested include paromomycin and trimethroprim-
sulfamethoxazole.
Keywords: Blastocystis, Pathogenicity, Treatment failure, Subtypes, ParasitologyIntroduction
Blastocystis is one of the most common intestinal protists
of humans. Blastocystis was first described 100 years ago
but surprisingly little is still known about the patho-
genicity, genetic diversity, host range and treatment.
First classified as yeast, Blastocystis was then subse-
quently classified as a protist and has now been placed
within the Stramenopiles [1-5]. Blastocystis has a world-
wide distribution with higher numbers being found in
developing countries probably due to poor sanitation
[6]. Blastocystis has been found in a wide range of ani-
mals including mammals, birds and amphibians. Up to
17 subtypes have been described with subtype (ST) 1–9
being found in humans [7]. ST3 is the predominant ST
found in most human epidemiological studies [8-10].
Due to the lack of knowledge about this parasite, there
is still controversy about whether to treat infections as
they may just be opportunistic colonisation. There has
been conflicting results about the efficacy of treatments
and this is an area where much more research is needed.
Blastocystis is transmitted by the faecal oral- route by
human- human or animal- human transmission. There* Correspondence: troberts@stvincents.com.au
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unless otherwise stated.have been several studies that have shown possible
transmission by contaminated water and it has been
stated that the poor provision of basic amenities plays
an important role in transmission [11-13]. A recent study
showed that 100% of people from low socio-economic
villages in Senegal were infected with Blastocystis sp.
suggesting that transmission was increased due to poor
hygiene sanitation, close contact with domestic animals
and livestock, and water supply directly from well and
river [10]. There are several methods for the detection
of Blastocystis. Microscopy of a permanent stain is the
gold standard for the diagnosis of Blastocystis in most
clinical laboratories. Microscopy was shown to have the
lowest sensitivity for the detection of Blastocystis (48%)
with PCR being the most sensitive technique used (94%)
[14]. Figure 1 describes a current view of the lifecycle of
Blastocystis.Pathogenicity
There is still much debate about the pathogenicity of
Blastocystis in humans. Though many authors have given
credit to it as a pathogen [15-18], there are still many that
doubt the role of Blastocystis in human disease [19,20].
The most common symptoms associated with Blastocystis
infection include diarrhoea, abdominal pain and vomiting.
There are many reports of single patients that show therel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain






Excystation occurs while in the 
large intestine where the cyst 
develops into amoeboid, vacuolar 
and granular forms.
Encystation occurs before being 
deposited in the faeces
Infection in humans and animals 
is initiated when the faecal cyst is 
ingested.
The cyst can be ingested through 
either contaminated water or 
food, or via direct transmission 
through human faeces.
cyst
Possible animal hosts 
of Blastocystis include 
chickens, rats and 
pigs amongst others.
Figure 1 Lifecycle of Blastocystis sp.
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Blastocystis being the only infection detected.
There have been several case reports suggesting that
Blastocystis is related to urticaria [4]. The amoeboid
forms of Blastocystis ST3 were found in a case of acute
urticaria and the authors suggested that cutaneous
symptoms may be caused by disruptions to the immune
homeostasis as the host produces an inflammatory re-
sponse against the amoeboid forms [21]. Another case
showed the presence of Blastocystis ST2 in a severe case
of gastrointestinal symptoms and chronic urticaria in
the absence of any other infectious agent. Symptoms
persisted after initial antibiotic therapy but were finally
eradicated after combined metronidazole and paromo-
mycin treatment [22]. A recent retrospective study re-
ported 8/80 (11%) Blastocystis infected patients to have
skin manifestations as well as gastrointestinal symptoms
[23]. Unfortunately this study relied solely on microscopy,
so no information on ST related to cutaneous lesions
can be gathered; however all of these studies do show the
potential for Blastocystis to cause cutaneous symptoms.
Case reports are summarised in Table 1.
It was recently suggested that gastrointestinal symptoms
related to Blastocystis might be ST related but results
remain inconclusive [8,31-33]. It was suggested thatST1 may be related to pathogenicity with a higher
subtype-symptom relationship being noted [34].
There have been conflicting reports on the pathogenicity
of ST2 with some studies showing high symptom- infec-
tion rates [22,33] whereas others have seen no link [35,36].
A study in Colombia showed that 100% of patients with
diarrhoea had ST2 where asymptomatic people all had
ST1 [37]. There have been two previous studies that have
suggested ST4 to be a pathogenic strain due to the high
incidence of this ST in patients with severe diarrhoea
[38,39]. It was also suggested that ST8 could be a patho-
genic strain. ST8 is a rare subtype found in humans and in
two studies has been related to severe symptoms [8,30].
Even though ST3 is the most common ST found in
humans, there is a low association between ST and symp-
toms shown by patients [8]. An animal study in rats
showed that ST1 was statistically related to pathogenicity
and that there may be pathogenic and non- pathogenic
strains within ST3 and ST4 [40]. These studies highlight
the need for more research in to the relationship between
ST and symptoms.
The whole genome for ST7 has been described [41].
This genome has shed light on some important pro-
cesses identifying genes coding for proteins that are
responsible for host protease inhibition. Proteins like
Table 1 Case reports of Blastocystis infection
Patient Clinical history Diagnosis Treatment Outcome Study
One 11 y.o male
and one 12 y.o male
Both presented with right lower
quadrant tenderness, anorexia,
abdominal pain, nausea, vomiting
Initially diagnosed with appendicitis.
Stool examination showed Blastocystis






24 y.o female Nine week history of urticaria,
hives, chronic diarrhoea, IBS
Initially diagnosed with cellulitis.
Treated with non-steroidal cream with
no recovery of symptoms. Presented
with hives and diagnosed as urticaria.
Extensive investigation showed 4 +
Blastocystis in her stool.
Metronidazole All urticarial and IBS
symptoms cleared
[24]
45 y.o female Four month history of
erythematous and pruriginous
lesions on trunk and limbs, mild
gastoenteric complaints
Diagnosed with urticaria. Extensive









32 y.o female Four year history of allegic rhinitis
and chronic urticaria, swelling in
pressure sites
Diagnosed with delayed pressure
urticaria. Treated with systemic
corticosteroids with only partial
clearance of symptoms. Stool
examination positive for Blastocystis
Metronidazole All urticarial symptoms
cleared
[26]
60 y.o female Four year history of
anaphylactoid reactions, severe
asthma and generalised urticaria
Diagnosed with chronic urticaria.
Extensive investigation identified
Blastocystis in the stool
Paromomycin All urticaria symptoms
cleared
[27]
74 y.o male Diarrhoea, abdominal pain,
nausea, fatigue and fever
Hospitalised. Stool were positive for
Blastocystis
Metronidazole Clearence of symptoms
after 10days
[18]
29 y.o female Six month history of morning
stiffness, pain and swelling of
joints, elbows, ankles, knees,
diarrhoea, abdominal pain and
vomiting
Treated for presumed infectious
arthritis of the knee. No improvement.
Microscopy of the synovial fluid and
stools both showed the presence of
Blastocystis.
Metronidazole After two weeks knee
inflammation subsided




24 y.o male Six week history of diffuse
abdominal pain and diarrhoea
Stool examination was positive for
Blastocystis and Endolimax nana.
Metronidazole Complete resolution of
symptoms 10days later
[29]
19 y.o male Three week history of hives,
abdominal pain for 2.5months
Diagnosed with acute urticaria.
Routine testing showed the presence
of Blastocystis in the stool ST3





20 y.o male Urticaria and flatulence Treated with antihistamines with no
success. Further investigation showed
Blastocystis ST2 in the stool. Initially
treated with metronidazole but
treatment failure appears to have
occured. Then treated with co-
trimoxazole with no success and










40 y.o female Hospitalised due to severe
diarrhoea and fever
Blastocystis ST8 infection diagnosed
from stool cultures. Treated with
metronidazole. Symptoms persisted
and the patient also noted bloating,
flatulence and abdominal pain.




All symptoms cleared [30]
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disturbing the intestinal homeostasis [42]. Further in-
formation will be gathered as more genomes are de-
scribed that can help determine the role of genes in the
potential pathogenicity of Blastocystis.
The study of host immunity to Blastocystis is under rep-
resented in the literature and offers many opportunities
for future study. For example, the study of physiological orgenetic factors of the host that may affect the outcome of
Blastocystis infection as a possible pathogenic organism.
Immune response and animal studies
Several lines of evidence shed light on the possible
mechanisms of pathogenesis. Blastocystis express cyst-
eine proteases which have been shown to be sensitive to
the inhibitors iodoacetamide and E-64 in azoceasein
Roberts et al. Gut Pathogens 2014, 6:17 Page 4 of 9
http://www.gutpathogens.com/content/6/1/17assays [43]. Cysteine proteases play important func-
tional roles in invasion of host cells, immune evasion,
pathogenesis, virulence and cell cycle regulation. It was
shown that proteases from Blastocystis isolates can de-
grade human secretory immunoglobulin A [44] and that
Blastocystis WR1 ST4 induces contact-independent
apoptosis, F-actin rearrangement and barrier function
disruption in IEC-6 cells [45]. There was shown to be
extensive variation in morphology and protease activity
between the two different STs, 4 and 7, of Blastocystis
[46] with the avian (ST7) isolates having almost twice as
much cysteine protease activity compared to the rodent
(ST4) isolates. These two STs were also shown to cleave
secretory IgA with cysteine and aspartic protease activ-
ities respectively. These results suggest the possibility of
Blastocystis proteases as virulence factors and that they
contribute to parasite survival in vivo by degrading neu-
tralising mucosal antibodies. Another study was able to
identify two cysteine proteases (a cathepsin B and a
legumain) secreted by ST7 which could be helpful in
the development of virulent and diagnostic markers as
well as targets for chemotherapy [47]. One study sug-
gested that 32 kDa proteases of ST3 could be virulence
factors responsible for protein degradation [48] while
another study suggested that the 29 kDa Blastocystis
antigen could be used as a marker for pathogenicity and
differentiate between symptomatic and asymptomatic
infections [49]. Higher levels of IgA in symptomatic in-
dividuals with Blastocystis compared to healthy asymp-
tomatic carriers has also been described [50]. A recent
study on the effect of Blastocystis on the expression of
interferon gamma and proinflammatory cytokines in the
cecal mucosa of rats showed a significantly upregulated
amount of gene transcription of type 1 and proinflamma-
tory cytokines IFN-γ, IL-12 and TNF-α. This suggests that
Blastocystis infection in rats stimulates specific local host
responses including T cells, monocytes/macrophages and/
or natural killer cells when exposed to antigens [51]. Sev-
eral mice studies have highlighted the effect of Blastocystis
on infected mice with weight loss and diarrhoea occurring
when mice were inoculated with high doses of Blastocystis
[52-54]. Another study showed that Blastocystis can in-
vade the lamina propria, submucosa and muscle layers
[55] while another study found elevated levels of hyaluron-
idase in rat urine infected with Blastocystis which suggests
invasion of the colonic epithelium with Blastocystis but
further investigation in humans is necessary to confirm
this [56]. One study highlighted the use of laboratory rats
as a good animal model for Blastocystis infection. They
showed how rats infected with ST1 showed histopatho-
logical changes at all the different doses given and sug-
gested that ST1 infection has pathogenic potential with
individual variation [57]. These studies show how ani-
mals can be used as a good model for pathogenicity butit is important to take in to consideration that mice are
not naturally infected with Blastocystis unlike rats
which are commonly found to harbour Blastocystis.
Blastocystis infection in immunodeficient patients
Infections of the gastrointestinal tract play a fundamental
role in the morbidity and mortality of acquired im-
munodeficiency syndrome (AIDS) and human immuno-
deficiency virus (HIV) patients. A much higher rate of
gastrointestinal tract infections has been described since
the first cases of HIV and AIDS were reported including
diarrhoea associated with parasitosis [58,59]. Diarrhoea
is one of the clinical manifestations in HIV infection and
usually tends to be chronic. Parasite induced diarrhoea is
prominent in AIDS patients and there is varying infection
rates due to geographical location with a high incidence in
developing countries (e.g. up to 95% of infected people
in Africa and only up to 50% in developed countries).
Suppressed immunological responses at the mucosal level
that hinder the intestinal non- specific defence mecha-
nisms in the gastrointestinal tract play a major role in
AIDS pathogenesis.
There have been several studies into the prevalence of
intestinal parasites in HIV and AIDS infected people
with varying results and in particular the incidence of
Blastocystis in these study populations. A study in Brazil
found 40% of patients in an HIV positive population to
be infected with at least one enteropathogen and some
with two or more present [59]. In this study though, only
one patient was infected with Blastocystis which suggests
that this protozoan may not be an opportunistic parasite
in HIV infected people. Another study in northern India
found only two patients (7.7%) of the study population to
be infected with Blastocystis with 19 of the 26 people stu-
died having parasitic infections [60]. Though this is not a
high incidence of the parasite in the population, it was
shown that in these two patients there were 10 or more
organisms seen per field of view and the presence of no
other pathogens suggested that Blastocystis was the cause
of diarrhoea in these patients. This is in comparison to
studies done in Africa which showed Blastocystis infection
to be at a higher rate in HIV positive patients compared to
a control group. A study in Senegal found Blastocystis in
only HIV infected patients with all but one suffering from
diarrhoea and with no other pathogens found in the sam-
ples. This study suggested that Blastocystis should be con-
sidered an opportunistic parasite [61]. Another African
study in an Ethiopian teaching hospital found there to
be an incidence of 14.1% of Blastocystis infection in
HIV/AIDS patients. There were no statistically signifi-
cant differences in the prevalence of parasites amongst
cases and controls except that of Blastocystis which was
significantly higher in HIV/AIDS patients. They con-
cluded that Blastocystis was a possible pathogenic agent
Roberts et al. Gut Pathogens 2014, 6:17 Page 5 of 9
http://www.gutpathogens.com/content/6/1/17in immunocompromised patients [62]. A more recent
study of intestinal parasites in HIV/AIDS patients in
Ethiopia showed that Blastocystis was the third most com-
mon parasite identified at 10.6% of the study population of
248 patients [63]. There were no Blastocystis infections
seen in the HIV negative group. Diarrhoea was a clinical
finding in 80.9% of the parasite positive patients. Another
study in Ethiopia showed that the presence of intestinal
parasite infections were significantly higher among HIV
positive people not on Antiretroviral Treatment (ART)
compared to those on ART [64]. Blastocystis was the
second most common parasite identified in the non
ART group at 12.8% positive and there was a significant
association between Blastocystis infection and symp-
toms of diarrhoea. A study in Iran showed that the oc-
currence of parasites in HIV positive patients was not as
high as seen in African countries with an infection rate
of only 18.4%. Of the parasites seen in this study
though, Blastocystis was the second most prevalent at
4.4% with most of these cases being seen in diarrhoea
positive patients [65]. In Indonesia a total of 318 HIV
positive patients were investigated for parasites and
Blastocystis was identified as the most common parasite
occurring in 73.6% of the patients [66]. Blastocystis was
found to be present in all CD4+ groups with either high
or low counts. A study in China identified Blastocystis
as the most common enteric parasite in both the HIV
positive and HIV negative groups but it was observed
that there was actually a higher percentage in the HIV
negative group [67]. This study also observed that co-
infection with Blastocystis and HIV created lower CD4
levels and higher IL-2 levels compared to the other co-
infections with parasites. A recent study on the STs
found in HIV/AIDS patients identified 19.8% of patients
positive for Blastocystis with ST3 being the most com-
mon subtype with 55% of isolates followed by ST4 with
25%, ST1 with 15% and ST2 with 5% [68]. The majority
of isolates belonging to ST3 is consistent with results
from most molecular epidemiological studies conducted
around the world.
Most of these studies show that Blastocystis is not
higher in the HIV/AIDS population than what was pre-
viously found in normal populations with Blastocystis
incidence ranging from 6-70% in developing counties.
There are also some problems in relation to accuracy of
these results with most studies relying on techniques such
as the less sensitive microscopy and culture. Although
these studies give varying results in respect to Blastocystis
infection in HIV/AIDS patients, this parasite should still
be considered as a cause of diarrhoea in these cases and
shows the significance of parasite infection in immuno-
suppressed patients.
A study on cancer patients and Blastocystis infection showed
that Blastocystis was acquired after the commencementof chemotherapy treatment. This study raises the possibil-
ity of opportunistic infections of Blastocystis in immuno-
compromised people [69]. Another study showed that
7.7% of cancer patients were infected with Blastocystis
with a slightly higher rate of detection found in the pre-
treatment group (9.7%) as opposed to the post-treatment
group (6.7%) [68]. Another study in France compared
the occurrence of Blastocystis in immunocompromised
patients with haematological malignancies (HM) and a
non immunocompromised control group. The study
showed that there was not a high level of difference be-
tween the two groups with prevalence values of 16% for
the HM group and 13% for the control group but there
was a difference in STs found within the groups. ST4
was the most common ST found in both the HM and
control group (66.7% and 58.3% respectively) followed
by ST3 (20%), ST6 (6.7%) and ST7 (6.7%) in the HM
group. In the control group the second highest was ST7
(16.7%) followed by equal number of ST1, ST2 and ST3
(8.3%) [70]. These studies show how Blastocystis can
easily be an opportunistic infection.
Irritable bowel syndrome and the role of Blastocystis
There have been several hypotheses and increasing studies
in the last few years relating the incidence of Blastocystis
infections with the prevalence of irritable bowel syndrome
(IBS) in patients. Due to Blastocystis causing symptoms
similar to those attributed to IBS such as diarrhoea, ab-
dominal pains and cramps and nausea it is easily seen
why an association with this parasite and IBS patients
could be made. It is also possible that the change in the
environment in the intestine caused by IBS may allow
for the conditions favoured by Blastocystis for growth.
It has been proposed that a possible mechanism for the
IBS- like symptoms might be the low-grade inflamma-
tion through persistent antigenic exposure in a chronic
Blastocystis infection [71]. It has also been suggested that
polymorphisms in genes encoding inflammatory cytokines
might have a role in the pathophysiology of IBS. A recent
study has suggested that there is a role in the etiology of
IBS from the association between IL-8 and IL-10 gene
polymorphisms in IBS- Blastocystis carriers [72]. One
study showed a possible link between Blastocystis and IBS
(with 95 IBS patients and 55 control cases) where there
was an infection rate of 46% in IBS patients and only
7% in the control group was shown [73]. There have
been several other studies which have shown the high
number of Blastocystis positive individuals in the IBS
group compared to the control group with rates of
71%, 76% and 49% with less than 20% in the control
groups [74-76].
A recent study performed in Mexico on IBS patients
showed an association between Blastocystis and patho-
genicity with 31% of IBS patients found to harbour
Table 2 Summary of treatments and efficacy for
Blastocystis infection
Treatment (Dose) Efficacy Reference
Iodoquinole (650 mg t.i.d) 0% [91]
Emetine (100 μg/ml) 50% [92]
Metronidazole (2000 mg s.i.d) 0% [93]
Metronidazole (1500 mg s.i.d) 100% [26]
Metronidazole (750 mg t.i.d) 100% [24]
Metronidazole (750 mg t.i.d) 100% [21]
Metronidazole (500 mg t.i.d) 100% [79]
Metronidazole (250- 750 mg t.i.d) 33% [80]
Metronidazole (750 mg t.i.d) 100% [81]
Metronidazole (1500 mg s.i.d) 80% [94]
Metronidazole (800 mg t.i.d) 0% [30]
Metronidazole (30 mg/kg twice daily) 67% [89]
Nitazoxanide (500 mg t.i.d) 100% [86]
Nitazoxanide (100-200 mg b.i.d for children
<12 yr, 500 mg b.i.d for >11 yr)
86% [88]
Nitazoxanide (500 mg t.i.d) 100% [95]
Ornidazole (500 mg t.i.d) 50% [96]
Paromomycin (25 mg/kg t.i.d) 100% [93]
Paromomycin (500 mg t.i.d) 100% [97]
Paromomycin (25 mg/kg t.i.d) 100% [82]
Paromomycin (1000 mg b.i.d) & MZ (750 mg t.i.d) 100% [25]
Saccharomyces boulardii (250 mg b.i.d) 78% [89]
Trimethroprim-SMX 22% [80]
Trimethroprim-SMX (6 mg/kg TMP, 30 mg/kg
SMX s.i.d)
95% [98]
Trimethropim- SMX (320 mg TMP, 1600 mg
SMX s.i.d)
93% [98]
Trimethroprim- SMX (80 mg TMP, 400 mg
SMX t.i.d)
100% [30]
Triple therapy (nitazoxanide, furazolidone and
secnidazole)
0% [90]
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ST1 and ST3 infections within this population which
are also common in most non- IBS populations. This
study therefore does not show an association between
subtype and IBS infection. A different study on the STs
associated with IBS showed a much higher incidence of
ST1 in the IBS group compared to the control group
but with an equal number of ST3 from both groups
[74]. Another study from Egypt highlights the preva-
lence of ST1, ST3 and ST4 in IBS patients with ST1
only being detected in the IBS group and not the con-
trol group and also showed that ST1 was statistically
more relevant to pathogenicity than the other STs [78].
In Colombia, 100% of IBS patients with Blastocystis
were identified as harbouring ST3 [37]. The differences
from these studies highlights that more research needs
to be done on IBS and Blastocystis STs associated with
disease but does suggest that there may be a role of
Blastocystis in IBS.
Treatment
Due to the controversy surrounding the potential
pathogenicity of Blastocystis and the self-limiting nature
of symptoms, the treatment of this disease is equivocal.
Metronidazole is the most frequently prescribed anti-
biotic for infections [24,79,80]. Various drug treatments
using metronidazole have been prescribed ranging from
250–750 mg three times a day for 10 days [81,82] or used
in combination with other drugs including paromomycin
[25] or trimethroprim- sulfamethoxazole (TMP-SMX)
[15]. There have been reports of resistance to metro-
nidazole [83,84] and the cyst form has been shown to
have resistance up to 5 mg/ml [85]. Nitazoxanide, a
broad-spectrum 5-nitrothiazole antiparasitic agent has
also been reported to be effective in treatment [86,87].
Other studies have shown the efficacy of emetine, fura-
zolidone, TMP-SMX, iodochlorhydroxyquin and pentami-
dine [80,88]. One study also showed the potential benefits
of Saccharomyces boulardii treatment on Blastocystis
infected children in Turkey [89]. A case study in Australia
of 18 patients showed that clearance of Blastocystis and
symptoms did not occur after treatment with either
metronidazole, iodoquinol or triple combination therapy
consisting of nitazoxanide, furazolidone and secnidazole
showing the lack of efficacy of several commonly used an-
timicrobials for the treatment of Blastocystis [90]. Table 2
summarises the efficacy of antibiotics from previous stud-
ies. This table shows the large variation and contradictory
results from the different studies with the same antibiotic
dose having different efficacies in different studies.
It has also been proposed that the different STs of
Blastocystis have varying susceptibility to antimicrobial
drugs [99]. There have been four in vitro studies looking
at susceptibility patterns of Blastocystis. Although thesestudies had a small number of study isolates, it was ap-
parent that different STs show different susceptibility
patterns and that metronidazole is not the most effective
treatment for Blastocystis infection [92,100-102].
Due to the uncertainty of whether this parasite is a
pathogen or not does make it difficult for physicians to
decide whether to treat the infection. There are several
online resources including The Blastocystis Research
Foundation (www.bhomcenter.org) which is helpful for
both physicians and patients with information about
symptoms and treatments and also presents some of the
implications of infection in relation to transmission within
families and households.
Treatment should be considered if there are chronic
symptoms of diarrhoea and abdominal pain in the absence
of other pathogens identified from the stool sample.
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first line treatment due to the large number of cases of
treatment failure and other antimicrobials such as
trimethroprim- sulfamethoxazole. There may be a cor-
relation between ST and sensitivity to drugs which is yet
to be addressed in studies.
Conclusions
It is clear from all these studies that there is still much
work to be done in the areas of pathogenicity, treatment
and control. As more information from the genome is
gathered there will be more opportunity to identify pos-
sible genes that transcribe for pathogenicity and treatment
resistance. A simple antimicrobial susceptibility test for
Blastocystis could help to assure the correct drug is ad-
ministered and not allow for resistance to develop. Diag-
nosis should be made by the use of PCR and treatment
should be considered when no other infectious agent can
be identified.
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